Suppr超能文献

内皮素受体拮抗剂CPU0213和维生素E可逆转FKBP12.6和肌浆网钙ATP酶2a的下调:蛋白激酶Cε过度磷酸化的作用

Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon.

作者信息

Li Na, Jia Nan, Dai De-Zai, Dai Yin

机构信息

Research Division of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China.

出版信息

Eur J Pharmacol. 2008 Sep 4;591(1-3):211-8. doi: 10.1016/j.ejphar.2008.06.080. Epub 2008 Jun 27.

Abstract

Downregulation of FKBP12.6 and sarcoplasmic reticulum Ca(2+) ATPase (SERCA2a) contributes to sudden cardiac death and heart failure. We aimed to test the hypothesis that (i) downregulation of FKBP12.6 and SERCA2a can be taken as molecular markers for drug interventions and (ii) such downregulation is produced by crosstalk between endothelin-reactive oxygen species and beta-adrenoceptors stimulation, mediated by hyperphosphorylation of protein kinase Cvarepsilon (PKCvarepsilon). Rat cardiomyocytes were incubated with isoproterenol (1 microM), endothelin-1 (0.1 microM) or hydrogen peroxide (10 microM) for 18 h, resulting in downregulation of mRNA and protein of FKBP12.6 and SERCA2a, as well as upregulation of PKCvarepsilon mRNA and phosphorylated PKCvarepsilon protein. These changes were reversed by an application of either propranolol (1 microM), endothelin receptor antagonist CPU0213 (1 microM) or vitamin E (1 microM). As indicated by the fluorescent dye Fluo3, diastolic Ca(2+) in rat ventricular myocytes was increased after incubation with isoproterenol (0.1 microM). The increased Ca(2+) in diastole was dramatically decreased by CPU0213. Thus, the downregulation of FKBP12.6 and SERCA2a, and hyperphosphorylation of PKCvarepsilon, appear to be related to crosstalk between over-activated endothelin-reactive oxygen species and a beta-adrenoceptor pathway. CPU0213 is beneficial in treating cardiac insufficiency and preventing cardiac arrhythmias possibly by normalizing hyperphosphorylation of PKCvarepsilon and abnormal FKBP12.6 and SERCA2a. The antioxidant activity of vitamin E was sufficient to normalize the levels of FKBP12.6 and SERCA2a and phosphorylation of PKCvarepsilon. Thus by testing with biomarkers FKBP12.6 and SERCA2a, we have shown that the endothelin receptor antagonist CPU0213 and the antioxidant vitamin E may relieve risk of lethal arrhythmias and heart failure by suppressing PKCvarepsilon.

摘要

FKBP12.6和肌浆网Ca(2+)ATP酶(SERCA2a)的下调会导致心源性猝死和心力衰竭。我们旨在验证以下假设:(i)FKBP12.6和SERCA2a的下调可作为药物干预的分子标志物;(ii)这种下调是由内皮素-活性氧与β-肾上腺素能受体刺激之间的相互作用产生的,由蛋白激酶Cε(PKCε)的过度磷酸化介导。将大鼠心肌细胞与异丙肾上腺素(1微摩尔)、内皮素-1(0.1微摩尔)或过氧化氢(10微摩尔)孵育18小时,导致FKBP12.6和SERCA2a的mRNA和蛋白下调,以及PKCε mRNA和磷酸化PKCε蛋白上调。应用普萘洛尔(1微摩尔)、内皮素受体拮抗剂CPU0213(1微摩尔)或维生素E(1微摩尔)可逆转这些变化。如荧光染料Fluo3所示,与异丙肾上腺素(0.1微摩尔)孵育后,大鼠心室肌细胞的舒张期[Ca(2+)]i升高。CPU0213可显著降低舒张期升高的[Ca(2+)]i。因此,FKBP12.6和SERCA2a的下调以及PKCε的过度磷酸化似乎与过度激活的内皮素-活性氧和β-肾上腺素能受体途径之间的相互作用有关。CPU0213可能通过使PKCε的过度磷酸化以及异常的FKBP12.6和SERCA2a正常化,对治疗心功能不全和预防心律失常有益。维生素E的抗氧化活性足以使FKBP12.6和SERCA2a的水平以及PKCε的磷酸化正常化。因此,通过用生物标志物FKBP12.6和SERCA2a进行检测,我们表明内皮素受体拮抗剂CPU0213和抗氧化维生素E可能通过抑制PKCε来减轻致命性心律失常和心力衰竭的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验